Abstract
In early phase clinical trials usually only the safety and tolerability of a new drug are investigated at first. We suggest a model with which safety, measured on a categorical scale, and efficacy, a binary response, can be evaluated simultaneously. Subsequently we derive locally optimal designs for this model. Additionally, we apply this model in a sequential approach and compare its features with approaches considering only one endpoint.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
